<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126003">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01826474</url>
  </required_header>
  <id_info>
    <org_study_id>PRO045-CLIN-01</org_study_id>
    <nct_id>NCT01826474</nct_id>
  </id_info>
  <brief_title>Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy</brief_title>
  <official_title>A Phase IIb, Open-label Study to Assess the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Multiple Subcutaneous Doses of PRO045 in Subjects With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prosensa Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prosensa Therapeutics</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Italy: National Institute of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see whether PRO045 is safe and effective to use as medication
      for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 45 in the DNA
      for the dystrophin protein.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase IIb, open-label, multiple-dose study. The study consists of two phases; a dose
      escalation phase (with subsequent dose-titration) and a 48-week treatment phase.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in 6 minute walk test</measure>
    <time_frame>after 48 weeks of treatment phase</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle function</measure>
    <time_frame>after 48 weeks of treatment phase</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>after 48 weeks treatment phase</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of upper limb</measure>
    <time_frame>after 48 weeks of treatment phase</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes questionnaire</measure>
    <time_frame>after 48 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>after 48 weeks of treatment phase</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>PRO045, cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.15 mg/kg until dose-titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO045, cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg until dose-titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO045, cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 mg/kg until dose-titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO045, cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6.0 mg/kg until dose-titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO045, cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9.0 mg/kg until move to 48 week treatment phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO045, cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>48 week treatment phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO045, 0.15 mg/kg/week</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>PRO045, cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO045, 1.0 mg/kg/week</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>PRO045, cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO045, 3.0 mg/kg/week</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>PRO045, cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO045, 6.0 mg/kg/week</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>PRO045, cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO045, 9.0 mg/kg/week</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>PRO045, cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO045, selected dose</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>PRO045, cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Duchenne muscular dystrophy resulting from a mutation correctable by treatment with
             PRO045 confirmed by a state-of-the-art DNA diagnostic technique covering all DMD gene
             exons, including but not limited to MLPA (Multiplex Ligation-dependent Probe
             Amplification), CGH (Comparative Genomic Hybridisation), SCAIP (Single Condition
             Amplification/Internal Primer) or HRMCA (High-Resolution Melting Curve Analysis), and
             correctable by PRO045-induced DMD exon 45 skipping in cultured skin-derived
             myo-converted fibroblasts.

          2. Ambulant boys aged at least 5 years on the day of first dosing able to walk for at
             least 230 meters in the 6 minute walking distance (6MWD) test at first screening
             visit and also at the baseline visit. In addition, 2 of the 3 pre-treatment 6MWD
             tests (screen 1, screen 2, baseline) must be within +/-30 metres of each other prior
             to first PRO045 administration.

          3. Adequate quality for biopsy (confirmed with MRI) of the lateral head of the
             gastrocnemius muscle. An alternative muscle may be considered for biopsy but only
             following discussion between the Principal Investigator and the Prosensa Medical
             Monitor.

          4. Life expectancy of at least 3 years after inclusion in the study.

          5. Glucocorticosteroid use which is stable for at least 3 months prior to first PRO045
             administration. Subjects must have been receiving glucocorticosteroids for at least 6
             months prior to the first PRO045 administration.

          6. Willing and able to adhere to the study visit schedule and other protocol
             requirements.

          7. Written informed consent signed (by parent(s)/legal guardian and/or the subject,
             according to the local regulations).

          8. In France, a subject will be eligible for inclusion in this study only if either
             affiliated to, or a beneficiary of, a social security category.

        Exclusion Criteria:

          1. Known presence of dystrophin in ≥5% of fibres in a pre-study diagnostic muscle biopsy
             (i.e. historic muscle biopsy taken prior to written informed consent for this study).

          2. Current or history of liver disease or impairment.

          3. Current or history of renal disease or impairment.

          4. At least two aPTT above ULN within the last month.

          5. Screening platelet count below the lower limit of normal (LLN).

          6. Acute illness within 4 weeks prior to first dose of PRO045 which may interfere with
             the study assessments.

          7. Severe mental retardation or behavioural problems which in the opinion of the
             investigator prohibits participation in this study.

          8. Severe cardiomyopathy which in the opinion of the investigator prohibits
             participation in this study. If a subject has a left ventricular ejection fraction
             &lt;45% at screening, the investigator should discuss inclusion of the subject with the
             Medical Monitor.

          9. Expected need for daytime mechanical ventilation within the next year.

         10. Use of anticoagulants, antithrombotics or antiplatelet agents.

         11. Use of idebenone or other forms of coenzyme Q10 within 1 month prior to the start of
             the screening for the study.

         12. Use of nutritional or herbal supplements which, in the opinion of the investigator,
             may influence muscle performance, within 1 month of the study.

         13. Use of any other investigational product or participation in another trial with an
             investigational product, within 6 months prior to the start of the screening for the
             study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giles Campion, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Prosensa Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wai Ling</last_name>
    <phone>+31 71 3322100</phone>
    <email>w.mo@prosensa.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>N Goemans, MD</last_name>
      <phone>+32 16 343845</phone>
      <email>nathalie.goemans@uz.kuleuven.be</email>
    </contact>
    <investigator>
      <last_name>N Goemans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Myologie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T Voit, MD</last_name>
      <phone>+33 142 165858</phone>
      <email>t.voit@institut-myologie.org</email>
    </contact>
    <investigator>
      <last_name>T Voit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E Mercuri, MD</last_name>
      <phone>+39 0630 155 340</phone>
      <email>eumercuri@gmail.com</email>
    </contact>
    <investigator>
      <last_name>E Mercuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E Niks, MD</last_name>
      <phone>+31 7152 62197</phone>
      <email>E.H.Niks@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>E Niks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>F Muntoni, MD</last_name>
      <phone>+44 207 405 9200</phone>
      <email>f.muntoni@ich.ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>F Muntoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Genetic Medicine International Centre for Life</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V Straub, MD</last_name>
      <phone>+44 191 241 8600</phone>
      <email>volker.straub@newcastle.ac.uk</email>
    </contact>
    <investigator>
      <last_name>V Straub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.prosensa.eu/home</url>
    <description>Prosensa website</description>
  </link>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>August 16, 2013</lastchanged_date>
  <firstreceived_date>March 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>DMD</keyword>
  <keyword>Prosensa</keyword>
  <keyword>Duchenne</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
